ZA947444B - Treatment of anxiety with the aid of (S)-(-)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide - Google Patents

Treatment of anxiety with the aid of (S)-(-)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide

Info

Publication number
ZA947444B
ZA947444B ZA947444A ZA947444A ZA947444B ZA 947444 B ZA947444 B ZA 947444B ZA 947444 A ZA947444 A ZA 947444A ZA 947444 A ZA947444 A ZA 947444A ZA 947444 B ZA947444 B ZA 947444B
Authority
ZA
South Africa
Prior art keywords
pyrrolidineacetamide
anxiety
oxo
alpha
ethyl
Prior art date
Application number
ZA947444A
Other languages
English (en)
Inventor
Ernst Wulfert
Jean Gobert
Alma Gower
Eric Cossement
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Sa filed Critical Ucb Sa
Publication of ZA947444B publication Critical patent/ZA947444B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
ZA947444A 1993-09-24 1994-09-23 Treatment of anxiety with the aid of (S)-(-)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide ZA947444B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939319732A GB9319732D0 (en) 1993-09-24 1993-09-24 Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety

Publications (1)

Publication Number Publication Date
ZA947444B true ZA947444B (en) 1995-05-11

Family

ID=10742476

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA947444A ZA947444B (en) 1993-09-24 1994-09-23 Treatment of anxiety with the aid of (S)-(-)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide

Country Status (17)

Country Link
US (1) US5447952A (cs)
EP (1) EP0645139B1 (cs)
JP (1) JP3688735B2 (cs)
KR (1) KR950007848A (cs)
AT (1) ATE191849T1 (cs)
AU (1) AU672334B2 (cs)
CA (1) CA2132509A1 (cs)
DE (1) DE69424009T2 (cs)
ES (1) ES2145818T3 (cs)
GB (1) GB9319732D0 (cs)
HU (1) HU217124B (cs)
NO (1) NO943521L (cs)
NZ (1) NZ264506A (cs)
RU (1) RU2142274C1 (cs)
SG (1) SG86284A1 (cs)
TW (1) TW283642B (cs)
ZA (1) ZA947444B (cs)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525347A (en) * 1995-01-31 1996-06-11 Medical University Of South Carolina Composition and methods for treating performance anxiety
CZ20021904A3 (cs) 1999-12-01 2002-11-13 Ucb, S. A. Pyrrolidinacetamidový derivát samotný nebo v kombinaci pro léčení poruch CNS
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
ATE413875T1 (de) * 2006-01-24 2008-11-15 Teva Pharma Zusammensetzungen enthaltend levetiracetam und verfahren zu deren herstellung.
CA2644010A1 (en) * 2006-03-15 2007-09-20 Actelion Pharmaceuticals Ltd Tetrahydroisoquinoline derivatives to enhance memory function
EP2051696A2 (en) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
PL2164847T3 (pl) * 2007-07-03 2012-02-29 Actelion Pharmaceuticals Ltd Związki 3-azabicyklo[3.3.0]oktanowe
RU2478099C2 (ru) * 2007-07-27 2013-03-27 Актелион Фармасьютиклз Лтд Производные 2-аза-бицикло[3.3.0]октана
EP2346500B1 (en) * 2008-10-16 2017-05-17 The Johns Hopkins University Methods and compositions for improving cognitive function
US8191547B2 (en) * 2008-10-23 2012-06-05 S-2Tech Llc Portable solar-heating system having an inflatable solar collector
US20100172979A1 (en) * 2008-12-24 2010-07-08 Zhongshui Yu Controlled-release formulations
US20100159009A1 (en) * 2008-12-24 2010-06-24 Zhongshui Yu Controlled-release formulations
CA2789014C (en) * 2010-02-09 2019-01-15 Michela Gallagher Methods and compositions for improving cognitive function
EP3400934A1 (en) * 2011-02-09 2018-11-14 The Johns Hopkins University Levetiracetam for improving cognitive function
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA
DK2968220T3 (da) 2013-03-15 2021-06-14 Agenebio Inc Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
CA2986598C (en) 2015-05-22 2023-09-26 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
US20220047548A1 (en) * 2018-12-04 2022-02-17 Metys Pharmaceuticals AG SYNERGISTIC COMPOSITIONS COMPRISING (R)-2-(2-OXOPYRROLIDIN-1-YL)BUTANAMIDE AND (S)-2-(2-e OXOPYRROLEDIN-1-YL)BUTANAMEDE IN A NON-RACEMIC RATIO

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1414845A1 (ru) * 1984-03-23 1988-08-07 Всесоюзный Научно-Исследовательский Химико-Фармацевтический Институт Им.С.Орджоникидзе 1-Тиокарбамоилметилпирролидин-2-тион,обладающий ноотропной активностью, и способ его получени
GB8412357D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
SU1320707A1 (ru) * 1985-01-24 1987-06-30 Ивано-Франковский Институт Нефти И Газа Способ определени износостойкости материалов ма тниковым склерометром
GB8827389D0 (en) 1988-11-23 1988-12-29 Ucb Sa Process for preparation of(s)alpha-ethyl-2-oxo-1-pyrrolidineacetamide
EP0408782A1 (en) * 1989-07-18 1991-01-23 Nauchnoissledovatelski Chimikopharmatzevtichen Institut Antihypoxic agent
CA2048003A1 (en) * 1990-08-21 1992-02-22 Serge Burner Tricyclic pyridone derivatives

Also Published As

Publication number Publication date
NZ264506A (en) 1997-09-22
ES2145818T3 (es) 2000-07-16
DE69424009D1 (de) 2000-05-25
RU2142274C1 (ru) 1999-12-10
TW283642B (cs) 1996-08-21
EP0645139A1 (fr) 1995-03-29
AU7416994A (en) 1995-04-06
ATE191849T1 (de) 2000-05-15
HUT68299A (en) 1995-06-28
HU217124B (hu) 1999-11-29
JP3688735B2 (ja) 2005-08-31
EP0645139B1 (fr) 2000-04-19
KR950007848A (ko) 1995-04-15
NO943521D0 (no) 1994-09-22
NO943521L (no) 1995-03-27
JPH07149639A (ja) 1995-06-13
AU672334B2 (en) 1996-09-26
US5447952A (en) 1995-09-05
SG86284A1 (en) 2002-02-19
GB9319732D0 (en) 1993-11-10
DE69424009T2 (de) 2000-09-14
CA2132509A1 (en) 1995-03-25

Similar Documents

Publication Publication Date Title
TW283642B (cs)
TW249226B (cs)
EP0563345A4 (en) Novel 4-arylpiperazines and 4-arylpiperidines
ZA925128B (en) Pyrrolidine derivatives,their preparation and medicaments containing them
GR3022072T3 (en) Treatment of neurodegenerative diseases
AU3354895A (en) Novel medicinal use of 5ht3 antagonist
GR3005470T3 (cs)
AU2806692A (en) Medicament for the treatment of anxiety
EP0424156A3 (en) Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
AU639322B2 (en) Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds
EP0469782A3 (en) Treatment of cataract with prostacyclin compounds
NO920984L (no) Fremgangsmaate for diastereoselektiv reduktiv pinakol-kobling av homokirale alfa-aminoaldehyder
ZA88639B (en) Substituted 3-phenyl-7h-thiazolo(3,2-b)(1,2,4)triazin-7-ones,a process for the preparation thereof,medicaments containing same and the use thereof,and also some intermediates formed in the preparation of the compounds mentioned
EP0377127A3 (de) Verwendung von Myricetin-3-0-beta-D-glucuronid als Arzneimittel
IN172911B (cs)
CY2065B1 (en) Use of naphthoxazines
GR3003065T3 (en) Use of n-((1-ethyl-2-pyrrolidinyl)methyl)-methoxy-5-sulfamoyl benzamide in the treatment of sterility
ZA917001B (en) Medicaments containing substituted 2-cyclohexene derivates and their use for the control of diseases
EP0291888A3 (en) 4-substituted 1-cyanomethylene pyrroloû4,3-e¨-benzo-azepins
TW234715B (cs)
ZA937179B (en) Tetrahydorindazolone pharmaceutical compositions
ES2103166A1 (es) Procedimiento para la obtencion de amidinohidrazonas biciclicas.
ZA839573B (en) Novel 6alpha-methylprednisolone derivatives and their manufacture and use
GR920300126T1 (cs)
AU8377691A (en) Use of N-(1-hexahydroazepinylalkyl)acetamides for the treatment of cholinergic transmission disorders